Companies Nuvectis Pharma, Inc.
Nuvectis Pharma (NVCT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Nuvectis Pharma, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,690,725FY2023
- $1,157,639FY2024
- $2,588,526FY2025
CEO total pay was $2,588,526 in fiscal 2025, up from $1,157,639 in fiscal 2024.
FY2025: salary $653,987 · bonus $539,539 · stock awards $1,395,000
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ron Bentsur | $653,987 | $539,539 | $1,395,000 | — | — | — | — | $2,588,526 |
| Chairman & CEO | ||||||||
| Enrique Poradosu | 483,381 | 265,860 | 837,000 | — | — | — | — | 1,586,241 |
| Chief Scientific & Business Officer | ||||||||
| Shay Shemesh | 483,381 | 265,860 | 837,000 | — | — | — | — | 1,586,241 |
| Chief Development and Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ron Bentsur | $2,588,526 | $1,157,639 | $2,690,725 | ↑ +1,430,887 |
| Enrique Poradosu | 1,586,241 | 1,814,813 | 1,563,400 | ↓ −228,572 |
| Shay Shemesh | 1,586,241 | 1,814,813 | 1,563,400 | ↓ −228,572 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract and retain qualified executive officers by providing competitive base salaries and annual bonuses tied to the achievement of specific Company goals and objectives. Long-term equity awards, primarily restricted stock, are granted to align executive interests with stockholder value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ron Bentsur | RSA | — | — | — | 250,000 | — | $1,395,000 |
| Enrique Poradosu | RSA | — | — | — | 130,000 | — | 1,088,100 |
| Enrique Poradosu | RSA | — | — | — | 150,000 | — | 837,000 |
| Shay Shemesh | RSA | — | — | — | 150,000 | — | 837,000 |
| Shay Shemesh | RSA | — | — | — | 130,000 | — | 1,088,100 |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Enrique Poradosu | RSU | 48,399 | — | $365,412 |
| Shay Shemesh | RSU | 48,399 | — | 365,412 |
| Enrique Poradosu | RSU | 60,000 | — | 453,000 |
| Shay Shemesh | RSU | 60,000 | — | 453,000 |
| Ron Bentsur | RSU | 96,759 | — | 730,530 |
| Enrique Poradosu | RSU | 115,000 | — | 868,250 |
| Shay Shemesh | RSU | 115,000 | — | 868,250 |
| Ron Bentsur | RSU | 120,000 | — | 906,000 |
| Enrique Poradosu | RSU | 130,000 | — | 981,500 |
| Shay Shemesh | RSU | 130,000 | — | 981,500 |
| Enrique Poradosu | RSU | 150,000 | — | 1,132,500 |
| Shay Shemesh | RSU | 150,000 | — | 1,132,500 |
| Ron Bentsur | RSU | 210,000 | — | 1,585,500 |
| Ron Bentsur | RSU | 250,000 | — | 1,887,500 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James OlivieroIndependent · Compensation · Audit (Chair) | $60,000 | $264,900 | $0 | — | — | $324,900 |
| Kenneth HobermanIndependent · Compensation (Chair) · Audit | 60,000 | 264,900 | 0 | — | — | 324,900 |
| Matthew KaplanIndependent · Compensation · Audit | 50,000 | 264,900 | 0 | — | — | 314,900 |
| Juan SanchezIndependent · Compensation · Audit · Newly elected | 12,500 | 178,500 | 0 | — | — | 191,000 |
| Ron BentsurEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $182,500 |
| Equity awards (grant-date value) | $973,200 |
| All other compensation | $0 |
| Total cost of the board | $1,155,700 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Nuvectis Pharma as a peer
Companies that benchmark against NVCT
No companies currently name NVCT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Nuvectis Pharma, Inc. | 2025 | Ron Bentsur | $653,987 | $1,395,000 | — | — | $2,588,526 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | — | — | — | — | — |
| 2025 | 2025-06-12 | — | — | — | — | — |
| 2023 | 2023-06-16 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | —a |
| 2025 | 2025-06-12 | —b |
| 2023 | 2023-06-16 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew Kaplan | Director | 2026-06-11 | A | 35,000 | $0 | $0 | Common | Form 4 ↗ |
| Juan Sanchez | Director | 2026-06-11 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| James Oliviero | Director | 2026-06-11 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Kenneth Hoberman | Director | 2026-06-11 | A | 35,000 | 0 | 0 | Common | Form 4 ↗ |
| Ron Bentsur | Director | 2026-06-30 | A | 12,500 | 20 | 250,000 | Common | Form 4 ↗ |
| Marlio Charles Mosseri | Greater-than-10% holder | 2026-06-30 | A | 50,000 | 18 | 916,000 | Common | Form 4 ↗ |
| Michael J. Carson | Vice President, Finance | 2026-08-03 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (26 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ron Bentsur. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 14. As printed: 2,588,526. View filing ↗
- Section 01, Enrique Poradosu. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 1,586,241. View filing ↗
- Section 01, Shay Shemesh. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table”. As printed: 1,586,241. View filing ↗
- Section 03, Ron Bentsur RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Enrique Poradosu RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Enrique Poradosu RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Shay Shemesh RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Shay Shemesh RSA. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, James Oliviero. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 324,900. View filing ↗
- Section 08, Kenneth Hoberman. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 324,900. View filing ↗
- Section 08, Matthew Kaplan. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 314,900. View filing ↗
- Section 08, Juan Sanchez. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 191,000. View filing ↗
- Section 08, Ron Bentsur. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Matthew Kaplan 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Juan Sanchez 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Oliviero 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kenneth Hoberman 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Bentsur 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marlio Charles Mosseri 2026-06-30. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael J. Carson 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-12. Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 15,662,222). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 14,561,983). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-16. Item 5.07 · say-on-pay result. As reported: — (votes for as printed: 8,984,698). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 182,500 + equity 973,200 + all other 0 = 1,155,700, summed across the director compensation table rows.
- Nuvectis Pharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Nuvectis Pharma, Inc.'s own proxy. As printed: 2,588,526. View filing ↗